Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

Larger outsourcing facilities, which are FDA-regulated and can create prescription-specific compounded drugs as well as bulk orders, must cease compounding, distributing or dispensing tirzepatide ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions. This association is being called “Ozempic blindness.” Experts are not entirely clear why ...

In another top story, a post hoc analysis of the SURPASS trials revealed that adults with type 2 diabetes who received tirzepatide had significantly greater reductions in urine albumin-to ...

Two recent tools in the battle for weight loss have been showing incredible results: Semaglutide and Tirzepatide. Stephanie Davison from Skin Envy Non-Surgical Weight Loss Center, and Registered ...

Zepbound, a brand-name version of tirzepatide, is part of a class of medications called glucagon-like peptide 1 (GLP-1) agonists. In 2023, the Food and Drug Administration approved it for weight ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

“It” being sex, of course. But shortly after beginning a regimen of compounded tirzepatide, the generic version of anti-obesity jabs like Mounjaro, in August, her hankering for hanky-panky vanishe ...

As a reminder, the 5 Study arms are as follows: "The ability to study two GLP-1 drugs - semaglutide and tirzepatide - in a single study that together comprise well over 90% of the global GLP-1 ...

The glucagon-like peptide 1 (GLP-1) agonist tirzepatide lowers the risk for cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF), whether ...